What is Molecular Partners?
Molecular Partners AG is a clinical-stage biotechnology firm focused on pioneering a novel class of protein-based therapeutics known as DARPin (Designed Ankyrin Repeat Protein) molecules. These custom-built drugs are engineered to overcome the limitations of traditional therapeutic modalities. The company has established strategic collaborations with prominent pharmaceutical entities to advance its DARPin pipeline across critical therapeutic areas, including ophthalmology, oncology, and infectious diseases. Molecular Partners' compounds are currently progressing through various stages of clinical and preclinical development, signaling a robust pipeline aimed at addressing significant unmet medical needs.
How much funding has Molecular Partners raised?
Molecular Partners has raised a total of $199.3M across 4 funding rounds:
Series A
$15.6M
Series B
$44.2M
Stock Offering
$108.3M
Share Placement
$31.2M
Series A (2007): $15.6M with participation from Index Ventures, Endeavour Vision, and BB Biotech Ventures
Series B (2009): $44.2M led by BB Biotech Ventures, Index Ventures, Endeavour Vision, and Essex Woodlands
Stock Issuance/Offering (2014): $108.3M, investors not publicly disclosed
Share Placement (2016): $31.2M, investors not publicly disclosed
Key Investors in Molecular Partners
BB Biotech Ventures
BB Biotech Ventures is a healthcare-dedicated venture capital firm that invests in private companies developing drugs and medical devices. They combine hands-on experience, active networking, and deep sector knowledge with a focus on value creation.
Index Ventures
Index Ventures is a venture firm investing in the next generation of entrepreneurs from seed to IPO, partnering with founders to build enduring companies. They invest in entrepreneurs globally, with offices in San Francisco and London.
Endeavour Vision
Endeavour Vision is a leading investment advisory firm specializing in transformative healthcare technologies, particularly in medical devices and digital health, empowering entrepreneurs to commercialize innovative solutions.
What's next for Molecular Partners?
The recent major strategic investment in Molecular Partners AG, alongside its significant total funding, positions the company for accelerated growth and pipeline advancement. This capital infusion is expected to fuel further clinical trials, expand research and development efforts, and potentially broaden strategic partnerships. The company's focus on a novel therapeutic platform suggests a trajectory aimed at disrupting established treatment paradigms and capturing significant market share in its target indications. Future developments will likely center on advancing lead candidates through late-stage clinical studies and securing regulatory approvals, potentially leading to commercialization and further rounds of financing or strategic acquisitions.
See full Molecular Partners company page
